Modification of Nasal Epithelial Potential Differences of Individuals with Cystic Fibrosis Consequent to Local Administration of a Normal CFTR cDNA Adenovirus Gene Transfer Vector

John G. Hay, Noel G. Mcelvaney, Juan Herena, Ronald Crystal

Research output: Contribution to journalArticle

115 Citations (Scopus)

Abstract

Mutations in the cystic fibrosis transmembrane conductance regulator gene (CFTR) manifest on the nasal epithelial surface of individuals with cystic fibrosis (CF) by Na+ hyperabsorption and diminished β-agonist-induced Cl¯ conductance, resulting in an abnormal bioelectric phenotype across the nasal epithelium. A clinical trial was conducted to determine if a replication-deficient, recombinant adenovirus vector containing a normal copy of the CFTR cDNA (AdCFTR) could, when administered to the nasal epithelium, correct the abnormal bioelectric phenotype. Nine individuals with CF received 2 × 105 to 2 × 108.5 plaque forming units of AdCFTR to the epithelium of one nostril. Measurements made included: baseline electrical potential difference (PD) between the surface of the nasal epithelium and the interstitial fluid, change in PD in response to amiloride, which inhibits apical Na+ channels, and change in PD in response to isoproterenol in a low Cl¯ solution, a measure of cAMP-regulated Cl¯ conductance. The functional integrity of the epithelium was evaluated by the PD response to ATP. Each individual served as their own control with measurements made in the nostril to be treated before AdCFTR administration, and in the contralateral untreated nostril. On the average, in the treated nostril over 2 weeks after the local administration of the adenovirus vector compared to measurements made in the same nostril before treatment, baseline PD decreased toward normal (–53.3 ± 4.0 to –34.6 ± 3.4, p = 0.01), response to amiloride decreased toward normal (36.9 ± 4.7 to 19.7 ± 3.0, p = 0.02), and response to low CI¯ and isoproterenol increased toward normal (–4.5 ± 1.5 to –9.1 ± 2.1, p = 0.05). There were no changes in response to ATP (–15.3 ± 2.7 to –15.8 ± 1.9, p = 0.39), suggesting that the epithelium remained functionally intact. Importantly, there were no significant changes in measurements made in the untreated nostril. While limited to the nasal epithelium, these data suggest an adenovirus vector can safely deliver sufficient CFTR cDNA function to improve the abnormal CF bioelectric phenotype.

Original languageEnglish
Pages (from-to)1487-1496
Number of pages10
JournalHuman Gene Therapy
Volume6
Issue number11
DOIs
Publication statusPublished - 1 Nov 1995
Externally publishedYes

Fingerprint

Cystic Fibrosis Transmembrane Conductance Regulator
Nasal Mucosa
Regulator Genes
Nose
Adenoviridae
Cystic Fibrosis
Individuality
Complementary DNA
Epithelium
Amiloride
Phenotype
Isoproterenol
Genes
Adenosine Triphosphate
Extracellular Fluid
Clinical Trials
Mutation

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Modification of Nasal Epithelial Potential Differences of Individuals with Cystic Fibrosis Consequent to Local Administration of a Normal CFTR cDNA Adenovirus Gene Transfer Vector. / Hay, John G.; Mcelvaney, Noel G.; Herena, Juan; Crystal, Ronald.

In: Human Gene Therapy, Vol. 6, No. 11, 01.11.1995, p. 1487-1496.

Research output: Contribution to journalArticle

@article{c067b43cdbbd4e02907c7c5a721cebc2,
title = "Modification of Nasal Epithelial Potential Differences of Individuals with Cystic Fibrosis Consequent to Local Administration of a Normal CFTR cDNA Adenovirus Gene Transfer Vector",
abstract = "Mutations in the cystic fibrosis transmembrane conductance regulator gene (CFTR) manifest on the nasal epithelial surface of individuals with cystic fibrosis (CF) by Na+ hyperabsorption and diminished β-agonist-induced Cl¯ conductance, resulting in an abnormal bioelectric phenotype across the nasal epithelium. A clinical trial was conducted to determine if a replication-deficient, recombinant adenovirus vector containing a normal copy of the CFTR cDNA (AdCFTR) could, when administered to the nasal epithelium, correct the abnormal bioelectric phenotype. Nine individuals with CF received 2 × 105 to 2 × 108.5 plaque forming units of AdCFTR to the epithelium of one nostril. Measurements made included: baseline electrical potential difference (PD) between the surface of the nasal epithelium and the interstitial fluid, change in PD in response to amiloride, which inhibits apical Na+ channels, and change in PD in response to isoproterenol in a low Cl¯ solution, a measure of cAMP-regulated Cl¯ conductance. The functional integrity of the epithelium was evaluated by the PD response to ATP. Each individual served as their own control with measurements made in the nostril to be treated before AdCFTR administration, and in the contralateral untreated nostril. On the average, in the treated nostril over 2 weeks after the local administration of the adenovirus vector compared to measurements made in the same nostril before treatment, baseline PD decreased toward normal (–53.3 ± 4.0 to –34.6 ± 3.4, p = 0.01), response to amiloride decreased toward normal (36.9 ± 4.7 to 19.7 ± 3.0, p = 0.02), and response to low CI¯ and isoproterenol increased toward normal (–4.5 ± 1.5 to –9.1 ± 2.1, p = 0.05). There were no changes in response to ATP (–15.3 ± 2.7 to –15.8 ± 1.9, p = 0.39), suggesting that the epithelium remained functionally intact. Importantly, there were no significant changes in measurements made in the untreated nostril. While limited to the nasal epithelium, these data suggest an adenovirus vector can safely deliver sufficient CFTR cDNA function to improve the abnormal CF bioelectric phenotype.",
author = "Hay, {John G.} and Mcelvaney, {Noel G.} and Juan Herena and Ronald Crystal",
year = "1995",
month = "11",
day = "1",
doi = "10.1089/hum.1995.6.11-1487",
language = "English",
volume = "6",
pages = "1487--1496",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "11",

}

TY - JOUR

T1 - Modification of Nasal Epithelial Potential Differences of Individuals with Cystic Fibrosis Consequent to Local Administration of a Normal CFTR cDNA Adenovirus Gene Transfer Vector

AU - Hay, John G.

AU - Mcelvaney, Noel G.

AU - Herena, Juan

AU - Crystal, Ronald

PY - 1995/11/1

Y1 - 1995/11/1

N2 - Mutations in the cystic fibrosis transmembrane conductance regulator gene (CFTR) manifest on the nasal epithelial surface of individuals with cystic fibrosis (CF) by Na+ hyperabsorption and diminished β-agonist-induced Cl¯ conductance, resulting in an abnormal bioelectric phenotype across the nasal epithelium. A clinical trial was conducted to determine if a replication-deficient, recombinant adenovirus vector containing a normal copy of the CFTR cDNA (AdCFTR) could, when administered to the nasal epithelium, correct the abnormal bioelectric phenotype. Nine individuals with CF received 2 × 105 to 2 × 108.5 plaque forming units of AdCFTR to the epithelium of one nostril. Measurements made included: baseline electrical potential difference (PD) between the surface of the nasal epithelium and the interstitial fluid, change in PD in response to amiloride, which inhibits apical Na+ channels, and change in PD in response to isoproterenol in a low Cl¯ solution, a measure of cAMP-regulated Cl¯ conductance. The functional integrity of the epithelium was evaluated by the PD response to ATP. Each individual served as their own control with measurements made in the nostril to be treated before AdCFTR administration, and in the contralateral untreated nostril. On the average, in the treated nostril over 2 weeks after the local administration of the adenovirus vector compared to measurements made in the same nostril before treatment, baseline PD decreased toward normal (–53.3 ± 4.0 to –34.6 ± 3.4, p = 0.01), response to amiloride decreased toward normal (36.9 ± 4.7 to 19.7 ± 3.0, p = 0.02), and response to low CI¯ and isoproterenol increased toward normal (–4.5 ± 1.5 to –9.1 ± 2.1, p = 0.05). There were no changes in response to ATP (–15.3 ± 2.7 to –15.8 ± 1.9, p = 0.39), suggesting that the epithelium remained functionally intact. Importantly, there were no significant changes in measurements made in the untreated nostril. While limited to the nasal epithelium, these data suggest an adenovirus vector can safely deliver sufficient CFTR cDNA function to improve the abnormal CF bioelectric phenotype.

AB - Mutations in the cystic fibrosis transmembrane conductance regulator gene (CFTR) manifest on the nasal epithelial surface of individuals with cystic fibrosis (CF) by Na+ hyperabsorption and diminished β-agonist-induced Cl¯ conductance, resulting in an abnormal bioelectric phenotype across the nasal epithelium. A clinical trial was conducted to determine if a replication-deficient, recombinant adenovirus vector containing a normal copy of the CFTR cDNA (AdCFTR) could, when administered to the nasal epithelium, correct the abnormal bioelectric phenotype. Nine individuals with CF received 2 × 105 to 2 × 108.5 plaque forming units of AdCFTR to the epithelium of one nostril. Measurements made included: baseline electrical potential difference (PD) between the surface of the nasal epithelium and the interstitial fluid, change in PD in response to amiloride, which inhibits apical Na+ channels, and change in PD in response to isoproterenol in a low Cl¯ solution, a measure of cAMP-regulated Cl¯ conductance. The functional integrity of the epithelium was evaluated by the PD response to ATP. Each individual served as their own control with measurements made in the nostril to be treated before AdCFTR administration, and in the contralateral untreated nostril. On the average, in the treated nostril over 2 weeks after the local administration of the adenovirus vector compared to measurements made in the same nostril before treatment, baseline PD decreased toward normal (–53.3 ± 4.0 to –34.6 ± 3.4, p = 0.01), response to amiloride decreased toward normal (36.9 ± 4.7 to 19.7 ± 3.0, p = 0.02), and response to low CI¯ and isoproterenol increased toward normal (–4.5 ± 1.5 to –9.1 ± 2.1, p = 0.05). There were no changes in response to ATP (–15.3 ± 2.7 to –15.8 ± 1.9, p = 0.39), suggesting that the epithelium remained functionally intact. Importantly, there were no significant changes in measurements made in the untreated nostril. While limited to the nasal epithelium, these data suggest an adenovirus vector can safely deliver sufficient CFTR cDNA function to improve the abnormal CF bioelectric phenotype.

UR - http://www.scopus.com/inward/record.url?scp=0028802876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028802876&partnerID=8YFLogxK

U2 - 10.1089/hum.1995.6.11-1487

DO - 10.1089/hum.1995.6.11-1487

M3 - Article

VL - 6

SP - 1487

EP - 1496

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 11

ER -